In a new exclusive report, Insights from Patients on GLP-1RA Medications and the Future of Obesity Treatment, Cure unveils the results of a survey that sheds light on how patients navigate costs, side effects, and lifestyle changes while embracing the transformative potential of these medications for weight loss.
In 2025, obesity remains one of the most critical health crises in the United States, affecting more than 40 percent of U.S. adults and driving rising health costs and economic burdens. Amid this epidemic, a transformative class of medications — GLP-1 receptor agonists (GLP- 1RAs) — has revolutionized weight loss and chronic disease management. Originally developed for diabetes, GLP-1RAs have become a lifeline for millions seeking effective, sustainable weight loss solutions.